Authors' recommendations: Non-Hodgkin lymphoma is a type of cancer that affects the immune system. Slow-growing lymphomas are described as indolent. Patients usually survive well for a long time after being diagnosed with an indolent lymphoma, but they are also less likely to be cured by treatment with chemotherapy drugs. In many cases, the lymphoma returns after treatment and patients may need repeat courses of treatment over several years. Idelalisib is a new drug that is already used to treat some types leukaemia. Studies have shown that it may also treat indolent non-Hodgkin lymphoma if it returns after a first course of chemotherapy treatment. Idelalisib blocks a protein that is important for some cancer cells and this may shrink the lymphoma or stop it growing for a time. It is given as a tablet twice daily along with standard chemotherapy treatments. Idelalisib is currently being studied to see how well it works and whether it is safe to use in people with lymphoma. If idelalisib is licensed for use in the UK, it will offer a new treatment for people whose disease has returned after initially responding to treatment.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/idelalisib-in-combination-with-bendamustine-and-rituximab-for-indolent-non-hodgkin-lymphoma-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)